Back to Results

Letermovir for secondary prophylaxis for CMV disease in solid organ transplant recipients


A pilot trial of the tolerability and clinical effectiveness of  letermovir when used for secondary prophylaxis to prevent  recurrent cytomegalovirus disease in solid organ transplant recipients

Therapeutic Area Cytomegalovirus Infection
Principal Investigator David R. Snydman, MD
Min Age 18 Years
Max Age 75 Years
Gender Any
Contact David R. Snydman, MD
More Information


Open label trial of letermovir for secondary prophylaxis for solid organ transplant recipients at risk of relapsing cytomegalovirus infection and disease 

Study Details

Inclusion Criteria

Solid organ transplant patient at risk for relapsing  CMV infection or disease, written informed consent, not enrolled in another clinical trial

Exclusion Criteria

creatinine clearance < 10 cc

Study Requirements

This is an open label trial to assess the tolerability and clinical effectiveness of letermovir when used in preventing relapsing CMV disease and infection in solid organ transplant recipients. Patients who consent will receive letermovir instead of the usual cmv secondary prophylaxis of ganciclovir or valganciclovir. There are no extra visits or study related activites except for two extra blood draws. Patients will be followed as they are per usual care. The only other activity will be to maintain pill counts for adherence and to take calls to assure compliance with the therapy and assess tolerability. Individual patient follow up will be 6 months from the time of enrollent and the treatment period will be 8 weeks.